Dr Reddy's Launches First-to-Market Generic Olopatadine 0.7% Eye Drops in US
核心洞察
Dr Reddy's Laboratories received FDA approval to launch a generic over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% for treating itchy eyes (搜索) caused by allergens.
This first-to-market launch expands the company's existing OTC eye-care portfolio, which already includes 0.2% and 0.1% strength formulations of the same antihistamine eye drop.
The generic targets the Pataday brand market, which recorded approximately $69.9 million in US sales over the latest 52-week period ending December 27, 2025.
Dr Reddy's Laboratories has secured FDA approval to launch a generic over-the-counter ophthalmic solution in the United States, marking a significant expansion of the company's eye-care portfolio. The Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% represents a first-to-market generic entry targeting seasonal allergy sufferers.
Product Specifications and Indications
The newly approved antihistamine eye drop is indicated for the temporary relief of itchy eyes (搜索) caused by common allergens including pollen, ragweed, grass, animal hair, and dander. The 0.7% concentration joins Dr Reddy's existing OTC eye-care offerings, which include Olopatadine Hydrochloride Ophthalmic Solution USP in 0.2% and 0.1% strengths.
"This launch adds to our current portfolio in the OTC eye-care space, which includes Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 per cent and 0.1 per cent strengths," stated Milan Kalawadia, CEO of North America Generics at Dr Reddy's Laboratories.
Market Opportunity and Strategic Positioning
The generic launch targets the established Pataday brand market, which recorded sales of approximately $69.9 million in the US for the latest 52-week period ending December 27, 2025, according to NIQ data. This market entry positions Dr Reddy's to capture share in the lucrative OTC allergy eye drop segment.
Kalawadia emphasized that the first-to-market launch demonstrates "the company's deep capabilities in bringing store-brand equivalents of OTC brands in the US market." This strategic approach allows the company to offer cost-effective alternatives to branded products while maintaining therapeutic equivalence.
Market Response
Despite the significant product launch, Dr Reddy's shares closed 0.33% lower at Rs 1,186.45 on the BSE, reflecting mixed market sentiment on the announcement day. The launch represents part of the company's broader strategy to expand its presence in the US generic pharmaceuticals market through specialized therapeutic areas.